Authors: de Wit, R Roberts, JT Wilkinson, PM de Mulder, PHM Mead, GM Fossa, SD Cook, P de Prijck, L Stenning, S Collette, L

Citation: R. De Wit et al., Equivalence of three or four cycles of bleomycin, etoposide, and cisplatinchemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European organization for research and treatment of cancer genitourinary tract cancer cooperative group and the medicalresearch council, J CL ONCOL, 19(6), 2001, pp. 1629-1640

Authors: Wylie, JP Cowan, RA Radford, JA Deakin, DP Harris, M Wilkinson, PM

Citation: Jp. Wylie et al., A doxorubicin-based regimen used in the treatment of elderly patients withhigh-grade non-Hodgkin's lymphoma, CL ONCOL-UK, 12(3), 2000, pp. 153-157

Authors: Decatris, MP Wilkinson, PM Welch, RS Metzner, M Morgenstern, GR Dougall, M

Citation: Mp. Decatris et al., High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: An effective first-line therapy with minimal toxicity, ANN ONCOL, 11(4), 2000, pp. 427-434

Authors: Horwich, A Oliver, RTD Wilkinson, PM Mead, GM Harland, SJ Cullen, MH Roberts, JT Fossa, SD Dearnaley, DP Lallemand, E Stenning, SP

Citation: A. Horwich et al., A Medical Research Council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma, BR J CANC, 83(12), 2000, pp. 1623-1629

Authors: Fossa, SD Stenning, SP Gerl, A Horwich, A Clark, PI Wilkinson, PM Jones, WG Williams, MV Oliver, RT Newlands, ES Mead, GM Cullen, MH Kaye, SB Rustin, GJS Cook, PA

Citation: Sd. Fossa et al., Prognostic factors in patients progressing after cisplatin based chemotherapy for malignant non-seminomatous germ cell tumours, BR J CANC, 80(9), 1999, pp. 1392-1399